Diana Varghese, MD, is an internal medicine fellow at the University of Maryland.

Primary Aldosteronism More Common Than Previously Believed, Requires Increased Screening

Primary aldosteronism (PA) is significantly more prevalent among patients with incident 

 than previously believed, according to recent data.

Endocrine Society (ENDO) Annual Meeting 2026

 in Chicago, Illinois, by Diana Varghese, MD, an internal medicine fellow at the University of Maryland in Rockville, these data challenge the commonly accepted image of PA as a rare condition with limited impact. Varghese and colleagues hope that the present study encourages further research into more widespread methods of screening.

“Traditionally, we have always considered primary aldosteronism as a very, very rare condition, but I think that is changing,” Varghese told 

in an exclusive interview. “We know even in primary care practice that the prevalence of primary aldo is 5-10% or even more, and it goes up to even 30% in tertiary care settings. The Endocrine Society guidelines from last year ask for everyone to screen for hypertension – it’s just an acknowledgement of how much we under-screen for this condition.”

Historically, the lack of screening and diagnosis of PA has been attributed in large part to its lack of easily identifiable features. Additionally, given its believed rarity, many clinicians have little exposure to the disease and therefore have limited knowledge regarding its management. The current diagnostic process involves screening, confirmatory testing, and subtype differentiation of unilateral from bilateral forms – the process itself can be fairly invasive, requiring adrenal venous sampling.

To address these issues, Varghese and colleagues conducted a retrospective cohort study via the Optum Labs Data Warehouse. The team collected data on adults with incident hypertension diagnosed between 2011 and 2023, as well as paired measurements of renin and aldosterone. Suppressed renin was defined as ≤1 ng/mL/h or <8 pg/mL, and positive screening was defined by suppressed renin with aldosterone ≥10 ng/dL. The team employed multivariable regression to identify predictors of positive screens.

A total of 9414 patients were identified with incident hypertension and laboratory results for paired renin and aldosterone. The mean age among the patients was 52 years (standard deviation [SD], 16 years), 56% were women, and 58% were White. Varghese and colleagues saw positive screening results in 819 patients.

Multivariable analyses revealed the following factors associated with positive screening:

Older age compared with age <25 years (ranging OR, 2.46; 95% CI, 1.16-5.21 for ages 25-34 to OR, 4.03; 95% CI, 1.49-10.91 for ages ≥75)

Hispanic/Latino ethnicity (OR, 1.36; 95% CI, 1.06-1.74)

Diabetes mellitus (OR, 1.26; 95% CI, 1.03-1.54)

Odds of positive PA screening were lower among patients with heart failure (OR, 0.54; 95% CI, 0.35-0.84). Additionally, positive screening odds were lower with RAAS inhibitors (OR, 0.78; 95% CI, 0.66-0.92) and higher with beta blockers (OR, 1.45; 95% CI, 1.23-1.71), calcium channel blockers (OR, 1.3; 95% CI, 1.1-1.52), and potassium supplementation (OR, 1.66; 95% CI, 1.28-2.16).

Ultimately, Varghese and colleagues noted that the positive screening rate was 9% among the patients screened in the study. The team also pointed out significant variation across clinical, demographic, and medication-related subgroups. They hope that these findings could inform further screening strategies by providing potential indicators.

“Because we are now screening more and more people, we have to see what resources are needed to help the clinicians and in general to help with understanding more about this,” Varghese said. “Further studies need to link screening to downstream health outcomes and healthcare utilization, and to assess whether broader or risk-based screening improves PA outcomes.”

Editors’ Note: Varghese reports no relevant disclosures.

Varghese D, Takagi M, Deng Y, et al. Screening Yield and Predictors of Positive Primary Aldosteronism Screening. Abstract presented at the Endocrine Society (ENDO) Annual Meeting 2026, Chicago, IL. June 13-15, 2026.

Reincke M, Bancos I, Mulatero P, Scholl UI, Stowasser M, Williams TA. Diagnosis and treatment of primary aldosteronism. Lancet Diabetes Endocrinol. 2021;9(12):876-892. 

Videos

Diana Varghese, MD, discusses her recent study noting a 9% prevalence of PA among patients with incident hypertension and providing targets for further screening strategies.

News

news page, resources on the topics of disease- and specialty-specific medical news and expert insight can be found. Content includes articles, interviews, videos, podcasts, and breaking news on health care research, treatment, and drug development.

Clinical

clinical page is a resource for content on every specialty, disease, and topic available on our medical news site.

Endocrinology

The HCPLive endocrinology page is a comprehensive resource for clinical news and insights on endocrine system conditions. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for diabetes, hormonal disease, and more.

This page also hosts content previously published by EndocrinologyNetwork. 


Hypertension

The HCPLive hypertension page is a resource for medical news and expert insights on high blood pressure. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for hypertension, and more.

Conference

 conference coverage page features articles, videos, and expert-led live coverage from major medical meetings throughout the year.

Eingun James Song, MD, is the director of clinical research for Frontier Dermatology. 

What is the Link Between Atopic Dermatitis and Asthma? With Eingun James Song, MD

Eingun James Song, MD, of Frontier Dermatology, spoke in a session presented at the 

2026 Revolutionizing Atopic Dermatitis (RAD) Conference

 in Nashville about the growing recognition of atopic dermatitis as a systemic inflammatory disease, with the session, titled ‘Connecting AD to Other Dermatologic Disorders and Related Comorbidities.’

, Song emphasized that clinicians should think beyond the skin when managing patients with atopic dermatitis, particularly given the disease’s well-established links to other type 2 inflammatory conditions such as asthma, food allergies, and allergic rhinitis. Drawing parallels to lessons learned in psoriasis, Song noted that dermatology providers are increasingly recognizing the importance of addressing comorbidities as part of comprehensive patient care.

“I think we've learned from psoriasis that even though this is a skin disorder, it is often associated with other systemic conditions, and to properly take care of patients more comprehensively,” Song explained. “We can't just be thinking about managing the skin, but also some of the other comorbidities that are associated with the disease.”

During the session, Song and fellow presenters focused on several of these key conditions linked with atopic dermatitis, including asthma, food allergies, and skin infections. The overall message of the talk, he noted, was that atopic dermatitis should not be viewed in isolation, but rather as one manifestation of a broader inflammatory process that can impact various organ systems.

A major focus of Song and his co-panelists’ presentation was the concept of the ‘atopic march,’ which describes the progression of atopic diseases over time. Traditionally, this model suggests that patients may develop eczema early in life before later experiencing food allergies, allergic rhinitis, and asthma. However, Song described the progression as not being universal, noting certain patients appear to be at greater risk than others. Those showing more severe atopic dermatitis and reporting a strong family history of atopic disease are among those most likely to experience progression to additional allergic conditions.

Song also pointed to data suggesting that earlier and more effective treatment of atopic dermatitis may alter the course of disease. He highlighted observational findings indicating medications targeting type 2 inflammation, including biologics, may be linked with lower rates of future asthma and allergic rhinitis. Although these findings have not yet been confirmed in dedicated prevention trials, Song described them as an important and provocative area of ongoing research that could reshape how clinicians think about early intervention.

From a practical standpoint, Song encouraged dermatology providers to routinely screen patients with atopic dermatitis for symptoms of asthma and assess disease control in those with an established diagnosis. Awareness of a patient’s broader comorbidity profile, he opined, can help to inform treatment decisions and facilitate collaboration with allergy specialists.

Disclosures: Song has previously reported serving as an investigator, consultant, and/or speaker for AbbVie, Alphyn Biologics, Amgen, Apogee, Arcutis, Bristol Myers Squibb, Boehringer Ingelheim, Dermavant, DermBiont, Galderma, Incyte, Janssen, LEO Pharma, MoonLake, Novartis, Ortho, Pfizer, Regeneron, Sanofi, Sun Pharmaceutical Industries, Timber Pharmaceuticals, and UCB.

Song E, Friedman A, Soung J. Connecting AD to Other Dermatologic Disorders and Related Comorbidities. Session presented at: 2026 Revolutionizing Atopic Dermatitis Conference; June 17-19, 2026; Nashville, TN.

Song emphasized that clinicians should think beyond the skin when managing patients with atopic dermatitis.

Atopic Dermatitis

Atopic Dermatitis condition center page, audiences can find a variety of coverage mediums for medical news and updates, including articles, video interviews, podcasts, and breaking news on dermatitis research, treatment, and drug development.

Dermatology

The HCPLive dermatology page is a resource for medical news and expert insights on skin disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for dermatologic conditions, and more.

Patrick Campbell is the editorial director of HCPLive. Patrick has spent years spearheading coverage surrounding cardiometabolic health and rheumatic disease for MJH Life Sciences. Before joining MJH Life Sciences in 2019, he spent time as a beat reporter and/or multimedia specialist with the Pocono Record, Star News Group, and NJ Advance Media. He is the executive producer for multiple HCPLive podcasts, including Diabetes Dialogue, Don't Miss a Beat, Kidney Compass, Medical Ethics Unpacked, The Medical Sisterhood, and Skin of Color Savvy. 


Follow him on Twitter @RealPatCampbell or reach him via email at PCampbell@mjhlifesciences.com.

Jonathan Silverberg, MD, MPH
Credit: George Washington University

Long-term extension and pediatric pharmacokinetic data for nemolizumab (Nemluvio) in 

Revolutionizing Atopic Dermatitis (RAD) 2026 Conference

 show more than 90% of EASI-75 responders maintained response through 104 weeks, partial skin responders at Week 16 continued improving through 2 years, and weight-based pediatric dosing in children aged 2 to 11 years achieved pharmacokinetic exposures matching adults and adolescents.

"Data from these analyses indicate that the safety in these subgroups was consistent with the overall safety profile of nemolizumab with no new signals emerging over the extended follow-up,” wrote Jonathan Silverberg, MD, MPH, and investigators who led the 104-week analysis. “In addition, one-third of patients discontinued treatment during the study period, suggesting that long-term benefit may be achievable for many patients."

LTE maintenance data: IGA and EASI responses sustained at 2 years

In the ARCADIA long-term extension (LTE) study (NCT03989206), post-hoc analyses examined outcomes in patients with partial or minimal skin response at Week 16 of the ARCADIA 1 and ARCADIA 2 phase 3 trials who rolled over to open-label nemolizumab 30 mg Q4W plus optional topical therapy.

Partial skin responders (N=290) showed EASI-75 rates rising from approximately 29.5% at LTE baseline to 83.8% at Week 80 and 75.7% at Week 104. Minimal skin responders (N=207) showed a similar trajectory with EASI-75 reaching 72.2% at Week 80 and 64.7% at Week 104.

In the cohort-level maintenance analyses from the LTE, among patients who had already achieved IGA 0/1, EASI-75, or EASI-90 at LTE baseline, over 80% maintained IGA 0/1 at Week 104, over 90% maintained EASI-75 response, and over 90% maintained EASI-90 response through Week 104.

 Safety was consistent with the established nemolizumab profile, atopic dermatitis flares, nasopharyngitis, COVID-19, and upper respiratory infections were the most common adverse events.

Pediatric pharmacokinetics, safety, and efficacy in children aged 2-11 years

A phase 2, multicenter, open-label pharmacokinetic and safety study enrolled 109 children with moderate-to-severe atopic dermatitis across 3 cohorts: 

Dose levels were weight-based, with 5, 10, or 15 mg Q4W in low-dose cohorts and 10, 20, or 30 mg in the high-dose cohort, and given with background TCS plus or minus topical calcineurin inhibitors for up to 52 weeks.

Systemic exposures trough nemolizumab concentrations in Cohorts 1.1 and 2 matched those observed in adults and adolescents from the ARCADIA program, confirming the extrapolation strategy underpinning the pediatric development plan.

Efficacy outcomes at Week 16 in Cohorts 1.1 and 2 included EASI-75 in 73.0% and 69.4% of patients, IGA success (IGA 0/1 with ≥2-point improvement) in 40.5% and 47.2%, and PP-NRS ≥4-point itch improvement in 59.5% and 72.2% of patients, respectively. Itch relief was observed as early as Week 1. All responses were sustained through Week 52.

Safety in the pediatric cohorts was favorable: no serious treatment-emergent adverse events (TEAEs) occurred, and only 2 severe TEAEs were reported across all 109 children. EASI-50 and EASI-90 improvements at Week 4 were sustained through Week 52 in all 3 cohorts. The findings are intended to support regulatory applications for the pediatric AD indication.

Silverberg JI, Stein Gold L, Thaçi D, et al. Continuous response with nemolizumab: efficacy and safety up to 104 weeks in patients with moderate-to-severe atopic dermatitis with partial and non-response in skin at 16 weeks. Presented at: Revolutionizing Atopic Dermatitis; Nashville, TN; June 17-19, 2026.

Thaçi D, Tauber M, Papp KA, et al. Long-term (up to 104 weeks) maintenance of itch and skin responses with nemolizumab treatment in patients with moderate-to-severe atopic dermatitis. Presented at: Revolutionizing Atopic Dermatitis; Nashville, TN; June 17-19, 2026.

Eichenfield LF, Zdybski J, Reich A, et al. Pharmacokinetics, safety, and efficacy of nemolizumab in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis. Presented at: Revolutionizing Atopic Dermatitis; Nashville, TN; June 17-19, 2026.

Articles

Nemolizumab long-term extension data in moderate-to-severe atopic dermatitis showed durable disease control through 104 weeks with no new safety signals. Patients with partial or minimal skin response at Week 16 continued to accrue benefit on open-label 30 mg Q4W, with EASI-75 rates rising into the mid-60% to mid-70% range by 2 years. Among baseline responders, >90% sustained EASI-75 and EASI-90 through Week 104. Pediatric phase 2 results supported weight-based dosing achieving adult-like exposures with rapid, sustained efficacy and favorable tolerability.

ARCADIA LTE data show nemolizumab maintains EASI-75 in over 90% of responders through 2 years and phase 2 pediatric data shed further light at RAD 2026.

Nemolizumab Data at RAD 2026 Shed Light on Long-Term Itch Control, Pediatric Benefit

Chair, American Lung Association Board of Directors, Director of Clinical Research at Waterbury Pulmonary Associates, and assistant clinical professor of medicine at Yale University School of Medicine and Quinnipiac University.

Anticipating Cytisinicline: First New Smoking Cessation Aid in Over 20 Years

The United States Food and Drug Administration (US FDA) is set to make a decision on 

 (Achieve Life Sciences), a plant-derived partial nicotinic acetylcholine receptor agonist submitted for approval as a smoking cessation pharmacotherapy, on June 20, 2026. If approved, it would be the first new FDA-approved pharmacotherapy for smoking cessation since varenicline received approval in 2006.

David Hill, MD, a pulmonologist with Waterbury Pulmonary Associates in Waterbury, Connecticut, and Chair of the American Lung Association National Board, spoke with 

 ahead of the decision. He described the current landscape as one where all 7 approved smoking cessation agents are now generic, keeping costs down but removing commercial incentive to actively promote them — shifting clinical focus toward treating the consequences of smoking rather than preventing them.

"Having more options is always good," Hill said. "When somebody fails a quit attempt or doesn't tolerate a particular agent, having another thing to add to the armamentarium is a good thing."

Cytisinicline acts as a partial agonist at the α4β2 nicotinic acetylcholine receptor — the same target as varenicline, which was itself developed using cytisine as a structural template. Hill noted that the available clinical trial data show a favorable safety profile, with quit rates in the 15–20% range. While not dramatic in absolute terms, he framed that figure in clinical context: cold-turkey cessation yields approximately 5% sustained abstinence in the literature, making a 3- to 4-fold improvement meaningful, and the average smoker requires multiple quit attempts before succeeding.

He also pointed to the decades-long real-world experience with cytisine — the same base compound — in Eastern Europe and roughly 30 other countries including the UK, Canada, and Germany as an additional layer of reassurance. "There is real-world experience with a similar compound that shows good safety and efficacy," Hill said. "It's not like a new agent that's gone through clinical trials but nobody's actually used it in the real world."

Beyond smoking, cytisinicline holds FDA Breakthrough Therapy designation for vaping cessation, an indication for which no approved pharmacotherapy currently exists. Hill called the unmet need significant. Vaping was initially positioned as a cessation tool but has instead introduced nicotine dependence to a new generation, and devices can deliver nicotine at concentrations far exceeding those in conventional cigarettes. In the absence of approved vaping cessation agents, clinicians currently rely on off-label use of smoking cessation therapies. Hill said formal approval of an agent with dedicated vaping cessation data would carry practical value beyond efficacy — including facilitating insurance coverage.

Hill also underscored that pharmacotherapy alone is rarely sufficient, recommending that any quit attempt be paired with counseling and structured support. The American Lung Association's Freedom From Smoking program is available online at lung.org for patients without access to local cessation programs.

Hill had no relevant disclosures to report.

Achieve Life Sciences. Achieve Life Sciences announces FDA acceptance of cytisinicline new drug application for treatment of nicotine dependence for smoking cessation [press release]. September 3, 2025. https://ir.achievelifesciences.com/news-releases/news-release-details/achieve-life-sciences-announces-fda-acceptance-cytisinicline-new

Walker N, Howe C, Bullen C, et al. Cytisinicline for smoking cessation: the ORCA phase 3 replication randomized clinical trial. 

Pulmonologist David Hill, MD, anticipates cytisinicline's approval ahead of its June 20 PDUFA date.

Pulmonology

Infectious Disease condition center page is a comprehensive resource for clinical news and insights on respiratory health. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for asthma, COPD, interstitial lung disease, COVID-19, and more.

Strategic Alliance Partnership

Jay Lieberman, MD, from University of Tennessee

What is the Role of Immunology in Atopic Dermatitis Care? With Jay Lieberman, MD

Jay A. Lieberman, MD, a professor at the University of Tennessee Health Science Center, highlighted the increasingly collaborative nature of atopic dermatitis care during a discussion at the 

, with the ways in which advances in immunology and systemic therapies are reshaping the relationship between dermatology and allergy/immunology being notable takeaways.

In discussion with the editorial team at 

, Lieberman described the historic divide between the 2 specialties as having narrowed considerably as the understanding of atopic dermatitis has shifted over time. With the emergence of biologics and targeted systemic medications for patients, both dermatologists and allergists are now approaching the disease through an immunologic lens. Lieberman explained while dermatologists have traditionally focused on cutaneous manifestations, the increasing emphasis on immune pathways and systemic disease has brought the specialties closer together.

“I think as we get these newer therapies and these systemic agents, and we learn about all these immunologic aspects of atopic dermatitis, dermatologists are at the forefront of this now,” Lieberman said. “And I think that difference in allergy and dermatology is really decreasing over time.”

A key theme of Lieberman’s discussion was the importance of considering the broader spectrum of comorbidities known to commonaly accompany atopic dermatitis. He encouraged clinicians to think beyond the skin and evaluate patients for conditions linked to the disease impacting treatment decisions. As more drugs demonstrate efficacy across multiple atopic and inflammatory diseases, Lieberman stated, understanding a patient’s complete disease burden has become increasingly necessary.

In his interview, Lieberman also reflected on how dramatically the therapeutic landscape has shifted over the course of his career. When he began training, treatment options for moderate-to-severe atopic dermatitis were described as limited, with few systemic treatments being accessible. Today, clinicians have access to a growing number of targeted agents designed to address the underlying immunologic mechanisms of disease, fundamentally changing how atopic dermatitis is managed.

From an allergy and immunology perspective, Lieberman described immune system biology as having long been central to specialty training and clinical practice. However, Lieberman highlighted the evolution of modern dermatology in a similarly manner, with today's dermatologists increasingly functioning as “immunodermatologists” as they incorporate complex immunologic concepts into patient care. In other words, Lieberman sees fewer differences between the specialties than in the past.

Disclosures: Lieberman has previously been associated with Novartis Pharmaceuticals, ABBVIE, Genentech, Aquestive Therapeutics.

Lieberman J, Hawkes J. Connecting AD to Other Dermatologic Disorders and Related Comorbidities. Session presented at: 2026 Revolutionizing Atopic Dermatitis Conference; June 17-19, 2026; Nashville, TN.

Lieberman J. How Should Clinicians Address the Link Between Atopic Dermatitis and Allergy? HCPLive. June 18, 2026. 

https://www.hcplive.com/view/how-clinicians-address-link-between-atopic-dermatitis-allergy-

At RAD2026, Lieberman notes advances in immunology and systemic therapies that are reshaping the link between dermatology and allergy/immunology.


A propensity-matched study shows dupilumab reduces gastrointestinal and endocrine IMID risk by 43-46% but raises psoriasis risk by 24%.

Dupilumab Reduces GI & Endocrine IMID Risk, But Raises Dermatologic IMID Signal in AD

Nancy Reau, MD, is Professor of Internal Medicine, Richard B. Capps Chair of Hepatology, Associate Director of Solid Organ Transplantation, and Section Chief of Hepatology at Rush University Medical Center.

Podcasts

Tatyana Kushner, MD, joins hosts Brown and Reau to discuss HDV testing gaps, bulevirtide approval, and the emerging delta hepatitis pipeline.

Hepatology

Hepatitis C

Hepatitis C page, resources on the topics of medical news and expert insight into HCV can be found. Content includes articles, interviews, videos, podcasts, and breaking news on hepatitis C virus research, treatment, and drug development.

podcasts page features a feed of medical news and interview podcast series, including DocTalk, Lungcast, Derm Discussions, and Heart Trials.

Liver Lineup: Updates & Unfiltered Insights

Introducing Liver Lineup: Updates & Unfiltered Insights — an exciting new podcast delivering timely, candid perspectives on the most pressing topics in the fast-moving world of hepatology. Created by Nancy Reau, MD, and Kimberly Brown, MD, and hosted by HCPLive, this series dives into the cutting edge of liver disease research, clinical care, and real-world practice.

Liver Lineup: HDV Diagnosis, Bulevirtide, and the Delta Pipeline

Ryan Livingston joined the MJH Life Sciences team in March of 2025, shortly after graduating from TCNJ with a bachelor’s degree in English. He enjoys creative writing, reading, and scuba diving. He can be reached at rlivingston@mjhlifesciences.com.

Data from the ongoing open-label extensions of PATHFNDR-1 and PATHFNDR-2, presented at ENDO 2026, highlight the drug’s efficacy in reducing IGF-1.

Hormonal Disorders

2-Year Paltusotine Data Confirms Efficacy, Safety for Acromegaly in Treatment-Naïve and SRL-Treated Patients

Diana Isaacs, PharmD, is an endocrine clinical pharmacist, director of Education and Training in Diabetes Technology, and codirector of Endocrine Disorders in Pregnancy at the Cleveland Clinic.

This episode covers recent approvals and updated indications allowing more treatment options for children with diabetes.

Type 1 Diabetes

Type 2 Diabetes

Diabetes Dialogue

Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives is a monthly podcast hosted by Diana Isaacs, PharmD, and Natalie Bellini, DNP, aimed at providing a regular roundup of the latest clinically applicable insights across diabetes and metabolic diseases, with a focus on leveraging technology to improve care.

Diabetes Dialogue: Teplizumab, Stelo, and Inhaled Insulin Afrezza for Pediatric Patients

Oksana Hamidi, DO, is an associate professor in the division of endocrinology and metabolism at the University of Texas Southwestern Medical Center.

Crinecerfont enabled sustained GC dose reductions over 2 years, with nearly 70% of adults with classic CAH reaching physiologic dosing.

Nearly 70% of Adults With Classic CAH Reach Physiologic GC Dosing With Crinecerfont

Lieberman, spoke at RAD 2026 about highlights from his session, ‘Connecting AD to Other Dermatologic Disorders and Related Comorbidities.'

Allergy

Allergy condition center page is a comprehensive resource for clinical news and insights on allergic and inflammatory diseases. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for food and seasonal allergies, as well as allergic asthma and related conditions.

How Should Clinicians Address the Link Between Atopic Dermatitis and Allergy?

Rachel Gafni, MD, is a senior research physician at the National Institutes of Health.

Gafni discusses the primary results of the phase 3 CALIBRATE trial, testing the investigational oral calcilytic in this difficult-to-treat disease state.

CALIBRATE: Encaleret Achieves Mineral Homeostasis in Patients With ADH1, With Rachel Gafni, MD

RAD 2026 analyses reveal the impact of CHE on patients' lives, including its financial effects and influence on treatment decision-making. 

CHE Imposes Heavy Occupational, Quality-of-Life, and Economic Burden on US Patients

Real-world data from the international TRACE study show 12 months of tralokinumab improved skin and quality-of-life outcomes.

Tralokinumab Improves Atopic Dermatitis Across Subgroups in TRACE study

Learn why controlling IBD matters more than feared side effects, and how biologics, monitoring, and whole-person care restore normal life.

Latest News

Primary Aldosteronism More Common Than Previously Believed, Requires Increased Screening

What is the Link Between Atopic Dermatitis and Asthma? With Eingun James Song, MD

Nemolizumab Data at RAD 2026 Shed Light on Long-Term Itch Control, Pediatric Benefit

Anticipating Cytisinicline: First New Smoking Cessation Aid in Over 20 Years

What is the Role of Immunology in Atopic Dermatitis Care? With Jay Lieberman, MD